Summit Therapeutics Inc. Shareholders' Equity
Summit Therapeutics Inc. (SMMT) had Shareholders' Equity of $629.98 million as of 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-23
- 2026-06-30: Stockholders' Equity Attributable to Parent $629.98M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $545.93M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $658.86M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $192.26M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $629.98M 10-Q · filed 2026-07-23 | |
| 2026-03-31 | $545.93M 10-Q · filed 2026-07-23 | |
| 2025-12-31 | $658.86M 10-Q · filed 2026-07-23 | |
| 2025-09-30 | $192.26M 10-Q · filed 2025-10-20 | |
| 2025-06-30 | $259.44M 10-Q · filed 2026-07-23 | |
| 2025-03-31 | $344.33M 10-Q · filed 2026-07-23 | |
| 2024-12-31 | $388.75M 10-Q · filed 2026-07-23 | |
| 2024-09-30 | $437.92M 10-Q · filed 2025-10-20 | |
| 2024-06-30 | $195.07M 10-Q · filed 2025-10-20 | |
| 2024-03-31 | $44.21M 10-Q · filed 2025-10-20 | |
| 2023-12-31 | $77.69M 10-K · filed 2026-02-23 | |
| 2023-09-30 | $99.38M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $119.60M 10-Q · filed 2024-10-30 | |
| 2023-03-31 | $133.48M 10-Q · filed 2024-08-06 | |
| 2022-12-31 | $126.65M 10-K · filed 2026-02-23 | |
| 2022-09-30 | $133.25M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $51.32M 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $64.41M 10-Q · filed 2023-08-09 | |
| 2021-12-31 | $83.28M 10-K · filed 2025-02-24 | |
| 2021-09-30 | $102.30M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $119.43M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $64.41M 10-Q · filed 2022-08-11 | |
| 2020-12-31 | $79.45M 10-K · filed 2023-03-09 | |
| 2020-09-30 | $38.55M 10-Q · filed 2021-11-15 | $36.86M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $53.60M 10-Q · filed 2021-11-15 | $51.95M 8-K · filed 2020-09-29 |
| 2020-03-31 | $68.41M 10-Q · filed 2021-08-12 | $66.69M 8-K · filed 2020-09-29 |
| 2019-12-31 | $78.86M 10-K/A · filed 2022-12-21 | $77.24M 8-K · filed 2020-09-29 |
| 2019-09-30 | $36.18M 10-Q · filed 2020-11-16 | |
| 2019-06-30 | $43.56M 10-Q · filed 2020-11-16 | |
| 2019-03-31 | $51.24M 8-K · filed 2020-09-29 | |
| 2019-01-31 | $57.59M 10-K · filed 2021-03-31 | $55.82M 8-K · filed 2020-09-29 |
| 2018-12-31 | $32.17M 10-Q · filed 2020-11-16 | |
| 2018-01-31 | -$3.59M 10-K · filed 2021-03-31 | -$4.46M 8-K · filed 2020-09-29 |
| 2017-01-31 | -$4.40M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |